DHHC22 mediates the S-palmitoylation of mTOR and reduces its stability in a time-dependent manner, thereby disturbing the PI3K/Akt/mTOR signalling pathway, inhibiting breast cancer cell proliferation and decreasing its resistance to neratini.131 Therefore, targeting DHHC22 is a powerful strategy for the treatment of breast cancer. The gene discussed is AKT1; the disease is breast cancer.